 |
|
Drug fends off kidney cancer progression
May 19, 2008New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments. The study was led by Robert Motzer, MD, an attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), who will present the findings on May 31 at the annual meeting of the American Society for Clinical Oncology.
"This study has given us a new and clearly useful tool for treating renal cell tumors, and everolimus is an important step forward in terms of disease management and quality of life for patients living with this disease," said Dr. Motzer.
Kidney cancer is among the ten most common cancers in both men and women. The American Cancer Society estimates that there will be about 54,390 new cases of kidney cancer diagnosed in the US in 2008, and that about 13,010 people will die from the disease.
Everolimus, a once-daily oral therapy, targets the mTOR protein, which acts as a central regulator of tumor cell division, cell metabolism, and blood vessel growth. It is currently being evaluated for the treatment of several other cancers including lymphoma and neuroendocrine tumors.
More than 400 patients participated in this study, all of whom had disease that had progressed with currently available targeted therapies sunitinib and/or sorafenib. Patients were randomized to receive everolimus or placebo. After six months, 26 percent of patients in the everolimus group had disease that had not progressed, compared to only 2 percent of the placebo group. The average difference in progression free survival was four months for everolimus, compared to 1.9 months for the placebo group.
In February, 2008, an independent monitoring committee stopped the Phase III trial after interim results were positive and allowed researchers to offer everolimus to the patients receiving placebo.
"For almost 20 years, we made no headway in the management of advanced kidney cancer," notes Dr. Motzer. "Recently, the identification of several new angiogenesis- targeted agents has provided us with new treatment options and an improved outlook for patients with advanced kidney cancer. Based on the results of this trial, everolimus could become another tool in our armamentarium and, in the future, kidney cancer is likely to be managed as a chronic disease with these types of treatment advances."
Everolimus was well tolerated by patients and the most common side effects were mouth ulcers, anemia, skin rash and weakness.
Memorial Sloan-Kettering Cancer Center
Everolimus, a once-daily oral therapy, targets the mTOR protein, which acts as a central regulator of tumor cell division, cell metabolism, and blood vessel growth. It is currently being evaluated for the treatment of several other cancers including lymphoma and neuroendocrine tumors.
More than 400 patients participated in this study, all of whom had disease that had progressed with currently available targeted therapies sunitinib and/or sorafenib. Patients were randomized to receive everolimus or placebo. After six months, 26 percent of patients in the everolimus group had disease that had not progressed, compared to only 2 percent of the placebo group. The average difference in progression free survival was four months for everolimus, compared to 1.9 months for the placebo group.
In February, 2008, an independent monitoring committee stopped the Phase III trial after interim results were positive and allowed researchers to offer everolimus to the patients receiving placebo.
"For almost 20 years, we made no headway in the management of advanced kidney cancer," notes Dr. Motzer. "Recently, the identification of several new angiogenesis- targeted agents has provided us with new treatment options and an improved outlook for patients with advanced kidney cancer. Based on the results of this trial, everolimus could become another tool in our armamentarium and, in the future, kidney cancer is likely to be managed as a chronic disease with these types of treatment advances."
Everolimus was well tolerated by patients and the most common side effects were mouth ulcers, anemia, skin rash and weakness.
Memorial Sloan-Kettering Cancer Center
Kidney Cancer Current Events and Kidney Cancer News RSSNew data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas
Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.
Stem cell protein offers a new cancer target
A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.
2-drug combination appears safe and active in metastatic kidney cancer
Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial.
Finding Will Improve Accuracy of Cancer Diagnosis
Van Andel Research Institute (VARI) investigators working in collaboration with Cleveland Clinic researchers have determined that two types of kidney tumors previously thought to be different diseases are actually variations of the same disease.
Does a person's insurance coverage affect their access to quality cancer care?
Does a person's insurance coverage affect their access to quality cancer care? According to researchers at Fox Chase Cancer Center, insurance coverage may not only affect a patient's access to health care, but also the quality of care they receive.
Robotic assisted kidney cancer surgery proves to be beneficial to patients
Fox Chase Cancer Center researchers find that outcomes of robotic assisted kidney cancer surgery, when performed by experienced surgeons at high volume centers, prove more beneficial to patients when compared to open surgery.
Getting down to cancer basics
Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes. The new example - a gene on the X chromosome called UTX - is found in 10% of cases of multiple myeloma and 8% of esophageal cancers.
Castrate resistant prostate cancer: New therapeutic approaches
Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden.
Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
Freezing kidney tumors-using a safe minimally invasive interventional radiology treatment that kills the cancer 100 percent effectively without surgery-should be the gold standard or first treatment option for all individuals with tumors that are 4 centimeters in size or smaller. And, this treatment-interventional cryoablation-is a viable option for people with larger tumors, according to two studies presented at the Society of Interventional Radiology's 34th Annual Scientific Meeting.
Roadkill study could speed detection of kidney cancer
Large-scale data mining of gene networks in fruit flies has led researchers to a sensitive and specific diagnostic biomarker for human renal cell carcinoma, the most common type of kidney cancer.
More Kidney Cancer Current Events and Kidney Cancer News Articles
 |
100 Questions & Answers About Kidney Cancer (100 Questions & Answers about) by Steven C. Campbell (Author) There are 37,000 cases of kidney (renal cell) cancer in the US and 13,000 related deaths annually. 100 Questions and Answers About Kidney Cancer explains all aspects of the disease resulting in full awareness of what to expect when battling kidney cancer. |
 |
Kidney Cancer: A New Approach (Home Use) Most people have two functional kidneys which help regulate electrolytes such as sodium, potassium, calcium, and magnesium. Kidney tumors may change these important functions and can lead to a diagnosis of kidney cancer. On this program we spend time with courageous patients who are coping with their kidney cancer by seeking a new approach. Kidney Cancer is part of the award winning public television series Healthy Body, Healthy Mind. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Standard Process Renafood 90 Tablets by Standard Process |
 |
Johns Hopkins Patients' Guide to Kidney Cancer (John Hopkins Medicine) by Michael A. Carducci (Author), Janet R. Walczak (Author) The Johns Hopkins Patients Guide to Kidney Cancer is a concise, easy-to-follow how to guide that puts you on a path to wellness by explaining kidney cancer treatments from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and provides valuable tools to help you to put together your plan of care. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment. |
 |
Kidney Cancer: The Silent Destroyer Directed By: (c) Information Television Network |
 |
Kidney Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Kidney Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Kidney Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Kidney Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Beating Kidney Cancer Together Sweatshirt XXX-Large White by Shop Zeus |
 |
Cure Kidney Cancer Keychain by Design a Product LLC Text on keychain: Cure Kidney Cancer * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
 |
DANGER CADMIUM CANCER HAZARD CAN CAUSE LUNG AND KIDNEY DISEASE AUTHORIZED PERSON by Accuform Signs ADHESIVE VINYL (VS) Stick with Adhesive Vinyl for light-duty applications. The ideal choice for a variety of indoor, and sheltered outdoor, marking needs. Easily mounts to all curved areas such as pipes, poles and secondary containers.Material Features: 4-mil thick surface printed matte surface. Permanent acrylic adhesive. Moisture-resistant. Service temperature range: -20°F to 140°F. Durability: 2 years outdoors. Square corners and scored backing for quick peel-off and application. |
 |
Faster Than Glucosamine Joint Health Supplement - 90 Ct Softgels, 4.5-Ounce Boxes by FASTER THAN GLUCOSAMINE "Clinical research indicates that Faster Than Glucosamine! or FTG capsules, may be the world’s most effective natural anti-inflammatory supplement. Faster Than Glucosamine! is NOT glucosamine which is a shellfish extract. Rather, FTG is formulated with an extract from beef. Many people have heard how omega3 and fish oils are healthy due to their anti-inflammatory properties and for this reason we are often told to eat more fish and less beef. However not all beef causes inflammation. Nature has provided very potent anti-inflammatory oils within beef, which are then used to make FTG. IMPROVEMENT IN JUST 2 WEEKS: At the 2007 Scripps Integrated Medical Conference in California, this beef extract was awarded the best paper out of the 90 papers presented due to the outstanding results... |
| © 2009 BrightSurf.com |